Please assess the completion status of the following clinical trial:

Trial Title: Effect of Long-term, High-dose N-acetylcysteine on Exacerbations of Bronchiectaisis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. subjects were aged 18-80 years old;~2. a diagnosis of idiopathic or post-infective bronchiectasis was made;~3. patients had at least two exacerbations in the past year and were in a stable state for at least 4 weeks prior to the primary enrollment.~Exclusion Criteria:~Patients were excluded if they fulfilled any of the following criteria: current smokers; cigarette smoking within 6 months; cystic fibrosis or other etiologies (such as immunodeficiency, allergic bronchopulmonary aspergillosis, traction bronchiectasis caused by emphysema, advanced pulmonary fibrosis, etc.); pulmonary function test results showing a forced expiratory volume in 1 s (FEV1) ≤ 30% of the predicted value; a history of severe cardiovascular or neurological disease; comorbidity with liver disease, kidney disease, malignant tumor, gastric ulcer, or intestinal malabsorption; a known allergy to N-acetylcysteine; pregnancy or lactation (for women); a history of prior macrolide use of more than 1 week; and poor compliance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- N-Acetylcysteine group (Type: ACTIVE_COMPARATOR): Participants received 600 mg of oral N-acetylcysteine BID for 12 months.
- Control group (Type: OTHER): Participants received as-needed therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).